Effective and well tolerated: where do these drugs fit now? - ScienceDirect

The Lancet Oncology

Volume 20, Issue 4, April 2019, Pages 469-470

The Lancet Oncology

https://doi.org/10.1016/S1470-2045(18)30901-X Get rights and content

References (10)

GM Duchesne et al.
Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Lancet Oncol
(2017)
F Saad et al.
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
Lancet Oncol
(2018)
R Saluja et al.
Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer. From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases
Urol Oncol
(2016)
B Tombal et al.
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Lancet Oncol
(2019)
M Hussain et al.
Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer
N Engl J Med
(2018)

There are more references available in the full text version of this article.

Cited by (0)

© 2019 Elsevier Ltd. All rights reserved.